Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NUVB |
---|---|---|
09:32 ET | 2213 | 3.41 |
09:34 ET | 1481 | 3.39 |
09:36 ET | 3730 | 3.41 |
09:38 ET | 2797 | 3.46 |
09:39 ET | 2063 | 3.46 |
09:41 ET | 2000 | 3.445 |
09:43 ET | 2410 | 3.44 |
09:45 ET | 700 | 3.445 |
09:48 ET | 29014 | 3.405 |
09:50 ET | 505 | 3.42 |
09:52 ET | 200 | 3.43 |
09:54 ET | 6753 | 3.42 |
09:56 ET | 1502 | 3.44 |
09:57 ET | 4891 | 3.42 |
09:59 ET | 100 | 3.425 |
10:01 ET | 1091 | 3.415 |
10:03 ET | 500 | 3.435 |
10:06 ET | 28899 | 3.425 |
10:08 ET | 2400 | 3.42 |
10:10 ET | 8718 | 3.41 |
10:12 ET | 1100 | 3.4198 |
10:14 ET | 5317 | 3.41 |
10:15 ET | 7813 | 3.415 |
10:17 ET | 100 | 3.415 |
10:19 ET | 1075 | 3.4111 |
10:21 ET | 13245 | 3.42 |
10:24 ET | 1161 | 3.41 |
10:26 ET | 214 | 3.4 |
10:28 ET | 200 | 3.405 |
10:30 ET | 500 | 3.41 |
10:32 ET | 5171 | 3.405 |
10:33 ET | 936 | 3.42 |
10:35 ET | 4131 | 3.43 |
10:37 ET | 13178 | 3.41 |
10:39 ET | 2028 | 3.43 |
10:42 ET | 1426 | 3.44 |
10:44 ET | 600 | 3.44 |
10:46 ET | 625 | 3.435 |
10:48 ET | 500 | 3.43 |
10:50 ET | 600 | 3.435 |
10:51 ET | 505 | 3.43 |
10:53 ET | 9396 | 3.415 |
10:55 ET | 4363 | 3.425 |
10:57 ET | 243 | 3.425 |
11:00 ET | 4054 | 3.435 |
11:02 ET | 3267 | 3.435 |
11:04 ET | 9974 | 3.435 |
11:06 ET | 441 | 3.435 |
11:09 ET | 6859 | 3.425 |
11:11 ET | 200 | 3.42 |
11:13 ET | 1772 | 3.415 |
11:15 ET | 4710 | 3.41 |
11:18 ET | 300 | 3.39 |
11:20 ET | 1390 | 3.39 |
11:22 ET | 3604 | 3.385 |
11:24 ET | 2114 | 3.37 |
11:26 ET | 15182 | 3.375 |
11:27 ET | 5133 | 3.385 |
11:29 ET | 1550 | 3.38 |
11:31 ET | 2918 | 3.375 |
11:33 ET | 300 | 3.37 |
11:36 ET | 4515 | 3.36 |
11:38 ET | 5382 | 3.385 |
11:40 ET | 600 | 3.3851 |
11:42 ET | 200 | 3.385 |
11:44 ET | 3397 | 3.385 |
11:45 ET | 2811 | 3.385 |
11:47 ET | 200 | 3.38 |
11:49 ET | 300 | 3.385 |
11:51 ET | 7672 | 3.385 |
11:54 ET | 300 | 3.39 |
11:56 ET | 200 | 3.38 |
11:58 ET | 4288 | 3.395 |
12:00 ET | 100 | 3.395 |
12:02 ET | 2244 | 3.405 |
12:03 ET | 40539 | 3.415 |
12:05 ET | 100 | 3.415 |
12:07 ET | 1695 | 3.425 |
12:09 ET | 100 | 3.425 |
12:12 ET | 100 | 3.42 |
12:14 ET | 2992 | 3.415 |
12:16 ET | 4482 | 3.41 |
12:18 ET | 1837 | 3.425 |
12:20 ET | 100 | 3.42 |
12:21 ET | 28227 | 3.425 |
12:23 ET | 100 | 3.425 |
12:25 ET | 100 | 3.425 |
12:27 ET | 3344 | 3.424 |
12:30 ET | 2296 | 3.43 |
12:32 ET | 725 | 3.435 |
12:34 ET | 400 | 3.435 |
12:36 ET | 4339 | 3.445 |
12:38 ET | 6274 | 3.435 |
12:39 ET | 825 | 3.435 |
12:41 ET | 391 | 3.435 |
12:43 ET | 100 | 3.435 |
12:45 ET | 966 | 3.435 |
12:48 ET | 200 | 3.43 |
12:50 ET | 3434 | 3.42 |
12:52 ET | 1195 | 3.415 |
12:54 ET | 5387 | 3.435 |
12:56 ET | 54531 | 3.425 |
12:57 ET | 10426 | 3.415 |
12:59 ET | 725 | 3.415 |
01:01 ET | 1100 | 3.415 |
01:03 ET | 600 | 3.415 |
01:06 ET | 695 | 3.41 |
01:08 ET | 200 | 3.41 |
01:10 ET | 500 | 3.41 |
01:12 ET | 800 | 3.41 |
01:14 ET | 400 | 3.41 |
01:15 ET | 3030 | 3.41 |
01:17 ET | 2518 | 3.405 |
01:19 ET | 630 | 3.405 |
01:21 ET | 500 | 3.4 |
01:24 ET | 201 | 3.405 |
01:26 ET | 700 | 3.405 |
01:28 ET | 7493 | 3.415 |
01:30 ET | 20191 | 3.425 |
01:32 ET | 508 | 3.425 |
01:33 ET | 500 | 3.425 |
01:35 ET | 9614 | 3.415 |
01:37 ET | 3366 | 3.4 |
01:39 ET | 400 | 3.4 |
01:42 ET | 25478 | 3.435 |
01:44 ET | 9589 | 3.42 |
01:46 ET | 4756 | 3.4208 |
01:48 ET | 100 | 3.42 |
01:50 ET | 5130 | 3.41 |
01:51 ET | 100 | 3.415 |
01:53 ET | 204 | 3.415 |
01:55 ET | 1800 | 3.415 |
01:57 ET | 500 | 3.42 |
02:00 ET | 200 | 3.42 |
02:02 ET | 2662 | 3.4 |
02:04 ET | 7653 | 3.4 |
02:06 ET | 200 | 3.405 |
02:08 ET | 700 | 3.41 |
02:09 ET | 650 | 3.405 |
02:11 ET | 1382 | 3.405 |
02:13 ET | 25244 | 3.405 |
02:15 ET | 510 | 3.405 |
02:18 ET | 1710 | 3.405 |
02:20 ET | 1452 | 3.405 |
02:22 ET | 12066 | 3.41 |
02:24 ET | 2880 | 3.405 |
02:26 ET | 54269 | 3.385 |
02:27 ET | 1422 | 3.385 |
02:29 ET | 9406 | 3.38 |
02:31 ET | 4286 | 3.39 |
02:33 ET | 600 | 3.395 |
02:36 ET | 1293 | 3.39 |
02:38 ET | 1043 | 3.395 |
02:40 ET | 17516 | 3.385 |
02:42 ET | 434 | 3.385 |
02:44 ET | 6035 | 3.385 |
02:45 ET | 655 | 3.39 |
02:47 ET | 700 | 3.39 |
02:49 ET | 14182 | 3.39 |
02:51 ET | 100 | 3.385 |
02:54 ET | 400 | 3.385 |
02:56 ET | 4624 | 3.39 |
02:58 ET | 146 | 3.385 |
03:00 ET | 500 | 3.385 |
03:02 ET | 2487 | 3.385 |
03:03 ET | 804 | 3.385 |
03:05 ET | 1000 | 3.385 |
03:07 ET | 11691 | 3.385 |
03:09 ET | 982 | 3.3825 |
03:12 ET | 1350 | 3.385 |
03:14 ET | 300 | 3.385 |
03:16 ET | 500 | 3.385 |
03:18 ET | 600 | 3.385 |
03:20 ET | 9322 | 3.36 |
03:21 ET | 300 | 3.365 |
03:23 ET | 336 | 3.36 |
03:25 ET | 200 | 3.365 |
03:27 ET | 5514 | 3.365 |
03:30 ET | 200 | 3.36 |
03:32 ET | 600 | 3.36 |
03:34 ET | 9119 | 3.365 |
03:36 ET | 506 | 3.36 |
03:38 ET | 19677 | 3.34 |
03:39 ET | 700 | 3.34 |
03:41 ET | 7167 | 3.325 |
03:43 ET | 46757 | 3.33 |
03:45 ET | 1099 | 3.32 |
03:48 ET | 5094 | 3.31 |
03:50 ET | 11637 | 3.3 |
03:52 ET | 2669 | 3.3 |
03:54 ET | 14111 | 3.29 |
03:56 ET | 11267 | 3.2805 |
03:57 ET | 33121 | 3.28 |
03:59 ET | 33073 | 3.28 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nuvation Bio Inc | 810.7M | -10.4x | --- |
Viridian Therapeutics Inc | 810.5M | -2.8x | --- |
Disc Medicine Inc | 820.0M | -9.8x | --- |
CARGO Therapeutics Inc | 827.3M | -7.2x | --- |
ProKidney Corp | 838.7M | -6.4x | --- |
ALX Oncology Holdings Inc | 781.5M | -4.0x | --- |
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $810.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 247.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.44 |
EPS | $-0.31 |
Book Value | $2.76 |
P/E Ratio | -10.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.